# Mirabegron

## Betmiga 25mg prolonged-release

| TAH Drug Code      | [**OBET2**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBET2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of overactive bladder with symptoms of urinary frequency, urgency, or urge urinary incontinence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | 25-50 mg once daily. May be taken with or without food. Swallow whole, do not chew/divide/crush.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to mirabegron or any component of the formulation, severe uncontrolled hypertension (systolic blood pressure >=180 mm Hg and/or diastolic blood pressure >=110 mm Hg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | >10%: Cardiovascular: Hypertension (9% to 11%) 1% to 10%: Cardiovascular: Tachycardia (2%) Central nervous system: Headache (4%), dizziness (3%) Gastrointestinal: Constipation (2% to 3%), xerostomia (3%), diarrhea (2%) Genitourinary: Urinary tract infection (3% to 6%), cystitis (2%) Neuromuscular & skeletal: Back pain (3%), arthralgia (2%) Respiratory: Nasopharyngitis (4%), sinusitis (3%) Miscellaneous: Flu-like syndrome (3%) <1% (Limited to important or life-threatening): ALT/AST increased, atrial fibrillation, breast cancer, cerebrovascular accident, GGT increased, glaucoma, LDH increased, leukocytoclastic vasculitis, lung cancer, nephrolithiasis, osteoarthritis, palpitations, prostate cancer, Stevens-Johnson syndrome, urinary retention, vaginal infection, vulvovaginal pruritus |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

## BETMIGA 50mg prolonged-release

| TAH Drug Code      | [**OBET5**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBET5)                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Neurogenic detrusor overactivity. Overactive bladder, Monotherapy or in combination with solifenacin, with symptoms of urge urinary incontinence, urgency, and urinary frequency.                                                                                                                                                                                                                                                          |
| Dosing             | 25-50 mg once daily. May be taken with or without food. Swallow whole, do not chew, divide or crush.                                                                                                                                                                                                                                                                                                                                       |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to mirabegron or any components of the product.                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common Cardiovascular: Hypertension (7% to 11.3% ), Tachycardia (1.2% to 2.2% ) Gastrointestinal: Constipation (1.2% to 4.7% ), Xerostomia (2.8% to 9.3% ) Neurologic: Headache (1.6% to 4.1% ) Renal: Urinary tract infectious disease (Adult, 2.9% to 8.4% ; pediatric, 24.4% ) Respiratory: Nasopharyngitis (3.5% to 5.8% ) Serious Neurologic: Cerebrovascular accident (0.4% ) Renal: Urinary retention Other: Cancer (0.1% to 1.3% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                               |

